Trial reportBMJ (Clinical research ed.)2001
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.
Trial report in BMJ (Clinical research ed.), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Design, Conduct, Analysis, and Reporting of Therapeutic Efficacy Studies in Visceral Leishmaniasis: A Systematic Review of Published Reports, 2000-2021.The American journal of tropical medicine and hygiene · 2024Pooled it
- Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.PLoS neglected tropical diseases · 2014Pooled it
- Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.PLoS neglected tropical diseases · 2017Trial
- Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™).The American journal of tropical medicine and hygiene · 2016Trial
- Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.PLoS neglected tropical diseases · 2014Trial
- Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial.PLoS neglected tropical diseases · 2014Trial
- Trial
- Structural analysis of ITS 1 gene ofFrontiers in cellular and infection microbiology · 2026Article
- Future implications of COVID-19 through Mathematical modeling.Results in physics · 2022Article
- In Vitro Susceptibility to Miltefosine ofMicroorganisms · 2021Article
- Threshold conditions for global stability of disease free state of COVID-19.Results in physics · 2021Article
- Threshold condition and non pharmaceutical interventions's control strategies for elimination of COVID-19.Results in physics · 2021Article
- Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?Microorganisms · 2020Review
- In vitro activity and mode of action of phenolic compounds on Leishmania donovani.PLoS neglected tropical diseases · 2019Article
- Review
- Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.The American journal of tropical medicine and hygiene · 2017Article
- Optimal control and cost-effective analysis of malaria/visceral leishmaniasis co-infection.PloS one · 2017Article
- Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis.Vaccine · 2016Article
- Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.Infectious diseases of poverty · 2016Review
- Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study.The American journal of tropical medicine and hygiene · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo test short course, low dose liposomal amphotericin B as single or daily infusion treatment in Indian visceral leishmaniasis (kala-azar).
designRandomised, open label study.
settingInpatient unit for leishmaniasis in Bihar, India.
participants91 adults and children with splenic aspirate positive for infection.
interventionsTotal dose of 5 mg/kg of liposomal amphotericin B given as a single infusion (n=46) or as once daily infusions of 1 mg/kg for five days (n=45).
main outcome measuresClinical and parasitological cure assessed 14 days after treatment and long term definitive cure (healthy, no relapse) at six months.
resultsAll but one person in each group had an initial apparent cure. During six months of follow up, three patients in the single dose group and two in the five dose group relapsed. Complete response (definitive cure) was therefore achieved in 84 of 91 subjects (92%): 42 of 46 patients in the single dose group (91%, 95% confidence interval 79% to 98%) and 42 of 45 in the five dose group (93%, 82% to 99%). Response rates in the two groups were not significantly different.
conclusionLow dose liposomal amphotericin B (5 mg/kg), given either as a five day course or as a single infusion, seems to be effective for visceral leishmaniasis and warrants further testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.